Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC)

被引：0
|
作者：
Gregorc, V.
Novello, S.
Santoro, A.
Grossi, F.
Levra, M. Giaj
Cavina, R.
Vigano, M.
Caligaris-Cappio, F.
Lambiase, A.
Bordignon, C.
机构：
[1] Ist Sci San Raffaele, Dept Oncol, Milan, Italy
[2] Univ Turin, Orbassano, Italy
[3] Ist Clin Humanitas, Rozzano, Italy
[4] Natl Inst Canc Res, Genoa, Italy
[5] Univ Turin, AUO San Luigi, Thorac Oncol Unit, Orbassano, Italy
[6] Ist Clin Humanitas, Dept Oncol, Rozzano, Italy
[7] MolMed SpA, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e18043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18043
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Santoro, A.
    Citterio, G.
    Pressiani, T.
    Gregorc, V.
    Rimassa, L.
    De Braud, F. G.
    Rossoni, G.
    Cappio, F. Caligaris
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 395 - 395
  • [22] Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC).
    Gregorc, Vanesa
    Zilembo, Nicoletta
    Grossi, Francesco
    De Pas, Tommaso M.
    Rossoni, Gilda
    Pietrantonio, Filippo
    Rijavec, Erika
    Citterio, Giovanni
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients (pts) with colorectal cancer (CRC) refractory to standard regimens
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Rimassa, L.
    Bennicelli, E.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [24] Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours
    V Gregorc
    A Santoro
    E Bennicelli
    C J A Punt
    G Citterio
    J N H Timmer-Bonte
    F Caligaris Cappio
    A Lambiase
    C Bordignon
    C M L van Herpen
    British Journal of Cancer, 2009, 101 : 219 - 224
  • [25] A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors
    De Braud, F. G.
    Gregorc, V.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [26] PHASE IB STUDY TO DEFINE THE OPTIMAL LOW DOSE OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), IN COMBINATION WITH CISPLATIN IN PATIENTS (PTS) WITH SOLID TUMOURS
    Gregorc, V.
    De Braud, F. G.
    De Pas, T. M.
    Citterio, G.
    Scalamogna, R.
    Boselli, S.
    Giovannini, M.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 160 - 160
  • [27] PHASE II STUDY OF NGR-HTNF, A NOVEL VASCULAR TARGETING AGENT (VTA), ADMINISTERED AS SINGLE AGENT AT LOW DOSE IN PATIENTS (PTS) WITH COLORECTAL CANCER (CRC) REFRACTORY TO STANDARD REGIMENS
    Rimassa, L.
    Sobrero, A.
    Santoro, A.
    Andretta, V.
    Gregorc, V.
    Sclafani, F.
    Caprioni, F.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136
  • [28] Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens
    Sobrero, A. F.
    Pessino, A.
    Andretta, V.
    Bennicelli, E.
    Fornarini, G.
    Caprioni, F.
    Comandini, D.
    Orsino, L.
    Lambiase, A.
    Bordignon, C.
    EJC SUPPLEMENTS, 2009, 7 (02): : 341 - 341
  • [29] A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC)
    Citterio, G.
    Santoro, A.
    Scalamogna, R.
    Pressiani, T.
    Gregorc, V.
    Rossoni, G.
    Donadoni, G.
    Caligaris-Cappio, F.
    Lambiase, A.
    Bordignon, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [30] Phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer (SCLC)
    Han, J.
    Lim, K. Y.
    Kim, H. Y.
    Han, J. H.
    Oh, S. H.
    Yun, T.
    Kim, H. T.
    Lee, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345